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dihydroxy, 5b-cholan-24-oic acid (Aramchol; Trima Israel Pharmaceutical Products Ltd, Maa-
barot, Israel) in a phase 2 trial of patients with nonalcoholic fatty liver disease (NAFLD).METHODS: We performed a randomized, double-blind, placebo-controlled trial of 60 patients with biopsy-
conﬁrmed NAFLD (6 with nonalcoholic steatohepatitis) at 10 centers in Israel. Patients were
given Aramchol (100 or 300 mg) or placebo once daily for 3 months (n[ 20/group). The main
end point was the difference between groups in the change in liver fat content according to
magnetic resonance spectroscopy. The secondary end points focused on the differences
between groups in alterations of liver enzyme levels, levels of adiponectin, homeostasis model
assessment scores, and endothelial function.RESULTS: No serious or drug-related adverse events were observed in the 58 patients who completed the
study. Over 3 months, liver fat content decreased by 12.57% – 22.14% in patients given
300 mg/day Aramchol, but increased by 6.39% – 36.27% in the placebo group (P[ .02 for the
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alanine aminotransferase and adiponectin, but homeostasis model assessment scores did not
change. The appropriateness of a single daily dose was conﬁrmed by pharmacokinetic analysis.CONCLUSIONS: Three months’ administration of the fatty acid–bile acid conjugate Aramchol is safe, tolerable,
and signiﬁcantly reduces liver fat content in patients with NAFLD. The reduction in liver fat
content occurred in a dose-dependent manner and was associated with a trend of metabolic
improvements, indicating that Aramchol might be used for the treatment of fatty liver disease.
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Nonalcoholic fatty liver disease (NAFLD) andnonalcoholic steatohepatitis (NASH) are increas-
ingly relevant public health issues because of their close
association with the worldwide epidemics of diabetes
and obesity.1 NAFLD/NASH is associated with liver-
related and cardiovascular morbidity and mortality,
and therefore is a burden on health expenditure in West-
ern countries. In the majority of patients, NAFLD/NASHis associated with additional features of the metabolic
syndrome.2 Histologically, NAFLD is characterized by
the presence of fat inﬁltration of the liver, expressed
by ballooning of hepatocytes. In approximately 20% of
cases it is accompanied by inﬂammation and hepatocyte
2086 Safadi et al Clinical Gastroenterology and Hepatology Vol. 12, No. 12injury, deﬁned as NASH, and liver ﬁbrosis progression.2
Despite the high prevalence of NAFLD, no safe and effec-
tive treatment currently is available.3 Adherence to life-
change modiﬁcations is difﬁcult to maintain.4 Bariatric
surgery can be performed in selective obese patients,
but is not recommended for treating NASH.5 Vitamin E
was found to be efﬁcient for nondiabetic NASH patients
without cirrhosis.6 The long-term safety and efﬁcacy of
pioglitazone are not clear in NASH.7,8 Metformin,9 urso-
deoxycholic acid, omega 3 fatty acids, and statins are
not considered as therapy for NAFLD/NASH patients.2,8
Aramchol (3b-arachidyl-amido, 7a-12a-dihydroxy,
5b-cholan-24-oic acid; Trima Israel Pharmaceutical
Products Ltd, Maabarot, Israel) is a novel synthetic lipid
molecule obtained by conjugating 2 natural components,
cholic acid (bile acid) and arachidic acid (saturated fatty
acid), through a stable amide bond. Aramchol signiﬁ-
cantly reduces hepatic fat content in animals with a high-
fat diet model.10 In in vitro models, Aramchol achieves
70% to 83% inhibition of the stearoyl coenzyme A
desaturase 1 (SCD1) activity. SCD1 is a key enzyme that
modulates fatty acid metabolism in the liver. SCD1 inhi-
bition decreases the synthesis and increases b oxidation
of fatty acids, resulting in decreased hepatic storage of
triglycerides and fatty acid esters.11,12
This process reduces liver fat and improves insulin
resistance in animals.13 In addition, Aramchol activates
cholesterol efﬂux by stimulating the adenosine triphos-
phate–binding cassette transporter A1, a pan-cellular
cholesterol export pump,10,14 and has shown to have
an anti-atherogenic effect in animal studies.15 In pre-
clinical studies, Aramchol in high doses did not cause the
severe adverse effects attributed to complete inhibition
of SCD1 (skin and eye disturbances, atherosclerosis, and
inﬂammation).16,17
In short-term clinical studies, no adverse events were
observed in 41healthy volunteers, testing single Aramchol
doses up to 900 mg and repeated doses up to 300 mg. We
hypothesize that the favorable safety proﬁle is attributable
to Aramchol’s partial inhibition of SCD1 activity and its
additional effect on the up-regulation of adenosine tri-
phosphate–binding cassette transporter A1. The current
study evaluated Aramchol’s effect on liver fat content
(LFC) and metabolic parameters in NAFLD patients.Patients and Methods
Study Design
Our study was a phase 2, multicenter, randomized,
double-blind, and placebo-controlled trial for 3 months in
10 Israeli medical centers. It aimed to evaluate the safety,
pharmacokinetics (PK), and effect of 2 Aramchol doses on
LFC in 60 subjects with NAFLD and NASH. This study was
designed and conducted according to the Good Clinical
Practice guidelines and following the protocol approval by
each Institutional Review Board and by the IsraeliMinistry of Health. Written informed consent was ob-
tained from all patients before any study-speciﬁc medical
procedures were performed. The trial is registered at
http://clinicaltrials.gov (NCT01094158) and was con-
ducted from December 2010 to December 2011.
The baseline evaluation included detailed medical
history and physical examination, height and weight
measurements for body mass index (BMI) calculation,
and blood analyses. Eligible patients were randomized
within 14 days of recruitment to receive a once-daily oral
dose of high-dose Aramchol (300 mg), low-dose Ara-
mchol (100 mg), or placebo. The medication was
administered in the morning within 10 minutes after
breakfast for 12 weeks. Randomization was performed in
12 balanced blocks of 6 subjects each, with 2 subjects per
treatment group in each block.
Subjects attended the clinic every 2 weeks for the
ﬁrst 2 visits followed by monthly visits for a total of 3
months. A follow-up visit was performed 1 month after
treatment completion for safety and liver enzyme eval-
uation. At each study visit, routine blood tests were ob-
tained, body weight and a physical examination were
recorded, and the number of pills was counted to docu-
ment compliance. Liver-related symptoms as well as
possible side effects of Aramchol were investigated.
Eligibility
This study was conducted in men and women aged
18 to 75 years with proven histology of NAFLD or NASH.
A percutaneous liver biopsy used for the diagnosis of
NAFLD or NASH was mandatory within 18 months
before the start of the study. All biopsy specimens were
assessed by a single hepatopathologist blinded to the
clinical and radiologic data, to randomization, and to
previous histologic assessments.
A NAFLD activity score, representing the sum of
scores for steatosis, lobular inﬂammation, and ballooning
(range, 0–8), was used to differentiate between NAFLD
and NASH. Subjects with a NAFLD activity score of 0 to
2 were considered to have NAFLD. An activity score of 3
or more was considered NASH. Fibrosis was staged as
follows: 0, none; 1, perisinusoidal or periportal; 2, peri-
sinus and periportal; 3, bridging ﬁbrosis; and 4, cirrhosis.
Efﬁcacy Evaluation
The primary efﬁcacy end point was the difference in
LFC, measured by magnetic resonance spectroscopy
(MRS), between baseline and the end of treatment. The
secondary efﬁcacy end points were the differences be-
tween baseline and the end of treatment in serum alanine
aminotransferase levels, endothelial function, measured
by ﬂow-mediated dilatation (FMD), insulin resistance,
measured by homeostasis model assessment, adiponectin
levels, hemoglobin A1C levels (HbA1C), weight, and
metabolic parameters such as serum cholesterol and
triglycerides.
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Baseline and post-treatment MRS were performed to
assess hepatic steatosis. Each MRS was performed using
point-resolved spectroscopy single voxel at the same
Medical Center on a GE 3T SignaHDxt scanner (Signa
Excite; GE, Milwaukee, WI) to minimize the impact of
scanner platform, ﬁeld strength, and other confounders
that frequently corrupt fat content estimations.18–20
Quantitative analysis of fat was performed using LC
Model software (version 6.3-0L; available at: http://www.
s-provencher.com/pages/lcmodel.shtml). The change
from baseline in LFC was calculated for each subject. The
mean change per group was calculated based on the in-
dividual changes. The primary end point was the differ-
ence between the study groups in the mean LFC changes.
Flow-Mediated Dilatation
A decrease in endothelial function, as observed in
NASH patients, plays a key role early in the development
of atherosclerosis and is an independent predictor of
cardiovascular risk.21–23 Endothelial function was
assessed at baseline and at the study end by FMD.
Brachial artery FMD was measured by induction of
reactive hyperemia using the temporary arterial occlu-
sion method. The resultant relative increase in blood
vessel diameter then was assessed via ultrasound.
Safety Evaluation
Safety evaluation included medical history, complete
physical examination and vital signs, clinical laboratory
evaluations (hematology, biochemistry), and electrocar-
diography. Adverse events were summarized and were
stratiﬁed by severity, outcome, and relation to study
drug.
Pharmacokinetic Analysis
PK assessment was performed on a third of the
studied population. Blood was collected at 3, 6, 12, and
24 hours after administration of the ﬁrst dose of Ara-
mchol and at time 0, 3, 6, 12, 24, and 72 hours after
administration of the last dose. Aramchol blood levels
were measured by liquid chromatography mass spec-
trometry at Analyst Laboratories (Rehovot, Israel).
PK analysis was performed using appropriate non-
compartmental methods. Standard PK parameters
(maximum plasma concentration; time to reach
maximum plasma concentration; the area under the
concentration vs time curve, calculated as the sum of
areas under the curve from time 0 to the last measurable
data point; the area under the concentration vs time
curve, calculated as the sum of areas under the curve
from time 0 to inﬁnity; and elimination half-life) were
calculated.Statistical Analysis
A sample size of 20 subjects per group provided a
power of 90% to identify a difference of at least 5% in the
triglyceride concentration decrease between the placebo
group and at least one of the treatment groups, with a
standard deviation of 5%. The sample size was considered
appropriate for the study: taking into consideration
possible drop-outs, a sample size of 17 patients in each
group still would have 80%power to detect a difference in
means of 5.0% reduction, assuming a standard deviation
of 5.0, with a 2-sided signiﬁcance level of 5%.24,25
Baseline parameters were compared between groups
using chi-squared test for sex and the number of patients
with NASH, and for all other variables using analysis of
variance (ANOVA). Efﬁcacy parameters were analyzed
using ANOVA and analysis of covariance models. A paired
t test was applied for testing changes within the study
groups in continuous parameters. The ANOVA model us-
ing the Dunnett method was applied for testing differ-
ences in measurements and changes from baseline
between the study groups. The analysis of covariance
model was applied for testing the differences between the
study groups in change of LFC and secondary outcomes,
adjusted for baseline measurement suspected to affect
LFC. All tests were 2-tailed, and a P value of 5% or lesswas
considered statistically signiﬁcant. The data were
analyzed using SAS version 9.1 (SAS Institute, Cary, NC).
All authors had access to the study data, and
reviewed and approved the ﬁnal manuscript.
Results
Patient Characteristics
Sixty patients with biopsy-proven NAFLD (n ¼ 54)
and NASH (n ¼ 6) were randomized. Two patients from
the Aramchol 100-mg group withdrew consent, resulting
in a sample size of 58 patients completing the study
(Supplementary Figure 1). Baseline parameters were
similar in all 3 treatment groups (Table 1).
At baseline, grade 1 ﬁbrosis was observed in 4 pa-
tients (20%) in the high-dose group, and in 5 patients
(25.0%) each in the low-dose group and in the placebo
group. Grade 2 ﬁbrosis was observed in 2 patients
(10.0%) in the low-dose group and in 3 patients (15.0%)
in the placebo group, and grade 3 ﬁbrosis was observed
in 2 patients (10.0%) each in the low-dose group and in
the placebo group. None of the patients in the high-dose
Aramchol group had grade 2 or 3 ﬁbrosis.
Efﬁcacy
A signiﬁcant dose-response relationship was
observed in the relative change in LFC among the 3
groups (P for trend by linear regression .01, adjusted for
age, sex, and BMI) (Figure 1A). Patients treated with
Table 1. Baseline Characteristics of the Study Population
Characteristic (normal range)
Aramchol
300 mg
(n ¼ 20)
Aramchol
100 mg
(n ¼ 18)
Placeboa
(n ¼ 19) P valueb
Age, y 38.4  14.6 39.7  11.7 42  11.2 .664
Males, n (%) 14 (70) 13 (72.2) 14 (73.7) .967
Weight, kg 84.5  16.2 86.7  10.0 83.7  11.4 .768
BMI, kg/m2 29.1  3.4 29.1  3 28.2  3.5 .646
MRS, g TG/100 g liver 0.27  0.07 0.25  0.07 0.22  0.08 .144
NASH, n (%) 2 (10) 2 (11.1) 2 (10.5) 1.0
Endothelial function, % 4.6  2.5 5.4  3.0 6.4  3.0 .213
ALT level, U/L (10–41) 78.3  41.6 74.4  43.6 63.1  31.2 .459
AST level, U/L (15–40) 47.8  33.8 40.2  15 38.8  16.4 .451
Alkaline phosphatase level, U/L (39–117) 75.7  17.8 72.1  25.6 73.5  24.5 .889
Glucose level, mg/dL (70–105) 95.6  12.9 99.1  16.2 96.1  10.9 .689
Cholesterol level, mg/dL (70–239) 193.6  43.5 178.7  49 187  40.7 .590
LDL, mg/dL 122.3  33.6 114.4  42.3 116.2  34.4 .786
HDL, mg/dL 43.5  19.8 40.5  7.9 41.6  7.6 .776
TG, mg/dL (50–199) 142.4  61.4 122  59.3 148.4  115 .60
Insulin level, mU/mL (5–25) 18.2  11.3 14.6  6.3 18.3  9.8 .404
HOMA score 4.4  3.7 3.7  2.1 4.4  2.7 .700
HbA1C, % 5.5  0.3 5.6  0.4 5.4  0.5 .498
Adiponectin level, mg/mL 3.8  2.8 3.9  2.1 4.2  2.9 .896
Albumin level, g/dL (3.5–5.1) 4.9  0.3 4.7  0.2 4.7  0.4 .098
NOTE. Continuous data are presented as the mean – standard deviation. Categoric data are presented as n (%).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HbA1C, hemoglobin A1C; HDL, high-density lipoprotein; HOMA, homeostasis model assess-
ment; LDL, low-density lipoprotein; TG, triglyceride.
aOne patient who completed the study was not included in the analysis due to major protocol deviations.
bP values for sex and the number of patients with NASH were determined by chi-squared test; P values for all other variables were determined by ANOVA.
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12.57%  22.14 in LFC compared with a 6.39%  36.27
increase in the placebo group (P ¼ .020). Individual
patient data on changes in LFC stratiﬁed by treatment
group are shown in Figure 1B, conﬁrming a different
pattern of relative change in LFC, predominantly a
decrease in the high-dose Aramchol group.
Differences between the 3 groups were analyzed for
secondary end points with adjustment for age, sex, and
baseline BMI. There were no statistically signiﬁcant dif-
ferences among the 3 treatment groups for any of theFigure 1. Relative change in MRS from baseline after 12 weeks
error of the mean LFC between baseline and end of treatment
covariance using the Dunnett method for the difference between
baseline BMI. (B) Individual patient absolute changes in LFC (m
baseline and 12 weeks of treatment stratiﬁed by the treatment g
change from baseline, after 12 weeks of treatment.secondary end points (Table 2). There was a nonsignif-
icant trend of mild weight reduction (P ¼ .1) in the high-
dose Aramchol group (Table 2). Serum adiponectin levels
increased (0.2  1.7 mg/mL) in the high-dose Aramchol
group but decreased in the low-dose (-0.3  1.5 mg/mL)
and placebo groups (-0.7  1.3 mg/mL) (P ¼ .088
for trend of dose-response relationship by linear
regression) (Figure 2). FMD increased nonsigniﬁcantly
by 1.28%  2.92% in the high-dose group, by 0.34% 
3.54% in the low-dose group, and by 0.46%  2.28% in
the placebo group.of treatment. (A) The relative change (percentage)  standard
(measured by MRS). P value was determined by analysis of
the Aramchol groups and placebo adjusted for age, sex, and
easured by MRS, triglycerides [in grams]/100 g liver) between
roup. P values refer to within-group comparisons of absolute
Table 2. Secondary Outcomes Change From Baseline, After 12 Weeks of Treatment
Variable
Aramchol
300 mg
(n ¼ 20)
Aramchol
100 mg
(n ¼ 18)
Placebo
(n ¼ 19)b
P valuea
300 mg
vs placebo
100 mg
vs placebo
FMD 1.28  2.92 0.34  3.54 0.46  2.28 .726 .987
ALT level, U/L -8.6  26.2 -7.8  30.5 -10.4  22.2 .926 .995
AST level, U/L -5.6  20.98 -1.56  13.55 -5.83  11.51 .923 .820
Alkaline phosphatase level, U/L -2.7  12.56 -2.06  7.34 1.67  6.16 .109 .218
Glucose level, mg/dL 0.1  12.03 -0.72  15.99 -1.06  9.77 .992 .999
Cholesterol, mg/dL 6.6  31.4 7.2  26 -0.5  24.3 .652 .631
LDL, mg/dL 7.3  34.9 -1.4  27 2  22.7 .780 .898
HDL, mg/dL 0.7  7 2.5  6.5 -0.9  3.7 .852 .257
TG, mg/dL -8.1  73 28.9  66.5 -7.6  67 .995 .186
Insulin, mU/mL -2.83  12.32 4.95  11.70 -0.24  4.73 .612 .292
HOMA score -0.80  3.81 1.13  3.42 -0.18  1.43 .733 .395
Hemoglobin A1C, % 0.12  0.34 0.02  0.29 0.11  0.34 .921 .430
Adiponectin, mg/mL 0.2  1.7 -0.3  1.5 -0.7  1.3 .163 .714
Weight, kg -1.15  2.25 0.08  2.41 0.21  2.29 .185 .990
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density
lipoprotein; TG, triglyceride.
aP values were calculated with ANCOVA using the Dunnett method adjusted for age, sex, and BMI.
bOne patient who completed the study was not included in the analysis due to major protocol deviations.
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The frequency of adverse events was similar in all
treatment groups, but none of them were considered to
be related to the treatment. All adverse events were mild
or moderate and none were serious (Table 3). None of
the patients withdrew as a result of adverse events.
Pharmacokinetics
PK analysis of both Aramchol doses was performed
on day 1 upon initiation of treatment as well as at the
end of treatment at week 13 (Figure 3).
Serum levels of the high-dose Aramchol were almost
twice the levels of the low-dose Aramchol. The predose
(trough) Aramchol serum levels of both doses remained
stable for the duration of treatment.Figure 2. Change in serum adiponectin levels from baseline in
each visit during 12 weeks of treatment: P value ¼ .088 for
the trend of dose-response relationship by linear regression
adjusted for age, sex, and baseline BMI.Discussion
In this randomized, double-blind, placebo-controlled
clinical trial, Aramchol was found to be safe and effective
in reducing LFC, as measured by MRS, in NAFLD patients
after 12 weeks of daily administration of 300 mg.
Because of the short therapeutic protocol, it is premature
to assess the clinical signiﬁcance of the effect of Ara-
mchol on liver fat reduction. However, liver fat reduction
alone has been shown to reverse NASH in studies with
effective weight reduction regimens26 and in patients
undergoing bariatric surgery.25,27 A regression in NASH
has been shown to accompany the decrease in LFC in
patients treated with thiazolidinedione, despite the fact
that the treatment did not result in a reduction in body
weight.24Table 3. Adverse Events: the Overall and the Most Frequent
Events (>2 Patients in Any Group)
Aramchol
300 mg
(n ¼ 20),
n (%)
Aramchol
100 mg
(n ¼ 20),
n (%)
Placebo
(n ¼ 20),
n (%)
Patients with adverse
events
9 (45.0) 8 (40.0) 11 (55.0)
Preferred term
Abdominal pain 1 (5.0) 1 (5.0) 2 (10.0)
Abdominal upper pain 2 (10.0) 1 (5.0)
Back pain - - 3 (15.0)
Constipation - - 2 (10.0)
Asthenia - - 2 (10.0)
Upper respiratory tract
infection
2 (10.0) - -
Figure 3. Average Aramchol plasma concentration vs time
proﬁles. PK analysis was performed in a third of the studied
population assigned by a centralized blinded randomization
as described in the Patients and Methods section.
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obesity, reduced glucose tolerance, type 2 diabetes mel-
litus, arterial hypertension, and hypertriglyceridemia.
NAFLD/NASH is not only considered the hepatic mani-
festation of the metabolic syndrome, but also an aggra-
vating factor for the insulin resistance that is its key
pathophysiological hallmark.28–30
Hyperinsulinemia, caused by insulin resistance, re-
sults in an increased hepatic de novo lipogenesis and
impaired inhibition of adipose tissue lipolysis, which
ultimately leads to an increased efﬂux of free fatty
acids from the adipose tissue to the liver.31 After the
initial fat inﬁltration, the liver becomes vulnerable to a
series of hits, leading to hepatocyte injury and ﬁnally
progressing from steatosis to NASH and ﬁbrosis. Such
multiple pathogenetic factors include oxidative damage,
dysregulated hepatocyte apoptosis, activation of the
proﬁbrogenic transforming growth factor b pathway,
dysregulation of adipokines, and hepatic stellate cell
activation.28,29
Our study measured several indicators of the meta-
bolic syndrome. No statistically signiﬁcant differences
were found between either of the 2 Aramchol treatment
groups and the placebo group for any of them (Table 2),
but an increase in adiponectin levels and a trend of
improvement in endothelial functionwere observed in the
high-dose treatment arm. Adiponectin has anti-oxidant,
anti-inﬂammatory, and antiﬁbrotic effects on the liver
and improves insulin sensitivity through peroxisome
proliferator-activated receptor activation.32,33 Hence, an
adiponectin increase might mediate the beneﬁcial Ara-
mchol mechanism.
Adiponectin levels and endothelial function are
decreased in NAFLD and NASH patients and the observed
trends of improvement after Aramchol treatment point at
possible positive metabolic effects of the compound, in
addition to its effect of LFC reduction.
Therefore, longer-term studies, with histologic and
metabolic end points, are warranted to assess Ara-
mchol’s effect on NASH and its metabolic complications.
PK studies conﬁrmed dose-proportional increases of
Aramchol in plasma levels with constant steady-statelevels throughout the study period and a long elimina-
tion half-life, conﬁrming suitability for once-daily
administration.
However, some trial limitations might be addressed
in the next planned phases, mainly the study population.
The current study included patients with mild NAFLD/
NASH disease. This might constitute a suboptimal target
population to test reduction of LFC and a signiﬁcant
effect on other metabolic derangements. Moreover, a
repeated liver biopsy within the short duration of the
study was considered unwarranted and thus no histo-
logic outcomes, including the important effect on ﬁbrosis,
can be discussed in this trial.
In conclusion, Aramchol at a dose of 300mgwas found
to be safe and effective in reducing LFC in NAFLD
andNASH patients and inducing trends of improvement in
metabolic parameters. This makes Aramchol a candidate
for the treatment of fatty liver–related diseases, currently
an unmetmedical need. Longer Aramchol trials in patients
with NASH and metabolic complications are warranted
for the study of metabolic and histologic beneﬁts.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2014.04.038.References
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